WCA
SWTX

Windsor Creek Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Windsor Creek Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8,068
Closed -$311 – 203
2019
Q4 		$311 Buy
+8,068
New +$189K 0.08% 115

Other funds holding SWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Windsor Creek Advisors's SWTX Position: Q1 2020 in Review

Windsor Creek Advisors sold out of SpringWorks Therapeutics (SWTX) in Q1 2020, closing a stake of 8,068 shares — an estimated $311 sold.

Windsor Creek Advisors first reported a position in SWTX in Q4 2019 and held it in 1 quarter. The position peaked at $311 in Q4 2019. 69 funds tracked by Wall St. Rank hold SWTX as of Q1 2020.

  • Windsor Creek Advisors reported no remaining SpringWorks Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Windsor Creek Advisors sold 8,068 SpringWorks Therapeutics shares in Q1 2020, an estimated $311.
  • Windsor Creek Advisors first reported a position in SpringWorks Therapeutics in Q4 2019 and held it in 1 quarter.
  • Windsor Creek Advisors's SpringWorks Therapeutics position peaked at $311 in Q4 2019.
  • 69 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2020.

Based on Windsor Creek Advisors's 13F filing for Q1 2020, filed 12 May 2020.